# Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule

> **NCT04768985** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 66 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Treatment A: Acalabrutinib tablet
- **DRUG:** Treatment B: Acalabrutinib capsule

## Key facts

- **NCT ID:** NCT04768985
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-25
- **Primary completion:** 2021-05-10
- **Final completion:** 2021-05-10
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2022-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04768985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04768985, "Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04768985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*